Perigon Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Perigon Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,058	Closed	-$274K	–	1316
2025 Q3	$274K	Buy	+5,058	New	+$289K	0.01%	1011
2021 Q2	–	Sell	-4,444	Closed	-$336K	–	516
2021 Q1	$336K	Buy	4,444 +3,695	+493%	+$302K	0.03%	366
2020 Q4	$66K	Buy	+749	New	+$59.4K	0.01%	656
2019 Q3	–	Sell	-2,709	Closed	-$232K	–	244
2019 Q2	$232K	Hold	2,709	–	–	0.05%	212
2019 Q1	$231K	Hold	2,709	–	–	0.05%	196
2018 Q4	$259K	Hold	2,709	–	–	0.07%	175
2018 Q3	$263K	Sell	2,709 -452	-14%	-$45.1K	0.06%	191
2018 Q2	$298K	Buy	+3,161	New	+$277K	0.09%	183
2017 Q4	–	Sell	-2,169	Closed	-$202K	–	610
2017 Q3	$202K	Sell	2,169 -4,137	-66%	-$366K	0.07%	198
2017 Q2	$573K	Buy	6,306 +330	+6%	+$30K	0.12%	160
2017 Q1	$525K	Buy	5,976 +811	+16%	+$72.2K	0.11%	173
2016 Q4	$485K	Buy	5,165 +506	+11%	+$43.5K	0.11%	179
2016 Q3	$431K	Buy	4,659 +536	+13%	+$50.5K	0.11%	156
2016 Q2	$321K	Buy	+4,123	New	+$351K	0.09%	167

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Perigon Wealth Management's BMRN Position: Q4 2025 in Review

Perigon Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,058 shares — an estimated $274K sold.

Perigon Wealth Management first reported a position in BMRN in Q2 2016 and held it in 14 quarters. The position peaked at $573K in Q2 2017. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Perigon Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Perigon Wealth Management sold 5,058 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $274K.
Perigon Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 14 quarters.
Perigon Wealth Management's BioMarin Pharmaceuticals position peaked at $573K in Q2 2017.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Perigon Wealth Management's 13F filing for Q4 2025, filed 16 Jan 2026.